Inimitable Ablexis Delivers Mice To Partners, Multiples To Investors
This article was originally published in Start Up
Executive Summary
Antibody platform play Ablexis has successfully built its technology, fulfilled a commitment to its pharmaceutical partners, triumphed in a lawsuit brought by one of biotech’s big boys, and lined the pockets of its investors. Surprisingly, it has no imitators.